Ovid CFO Form 3 reveals initial share and option stakes
Ovid Therapeutics Inc. filed an initial ownership report for Chief Financial Officer Charles Ross, detailing his equity position in the company.
Rhea-AI Filing Summary
Ovid Therapeutics Inc. filed an initial ownership report for Chief Financial Officer Charles Ross, detailing his equity position in the company. He directly holds 44,375 shares of common stock, including 34,375 restricted stock units that vest in three equal annual installments starting on February 20, 2027.
Ross also holds employee stock options covering 206,250 shares at an exercise price of $1.65 per share, expiring on March 25, 2036, and options on 200,000 shares at $1.14 per share, expiring on October 13, 2034. These options vest in monthly installments over multi-year periods, aligning his compensation with longer-term company performance.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Carter Charles Ross
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 406,250 contracts (Direct);
Common Stock — 44,375 shares (Direct)
Footnotes (3)
- F1. Includes 34,375 restricted stock units ("RSUs"). The RSUs will vest in three equal annual installments commencing on February 20, 2027, subject to the Reporting Person's continuous service through each such vesting date.
- F2. 25% of the shares subject to the Stock Option vested on October 14, 2025 and the remaining shares vested or will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date.
- F3. The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 26, 2026, subject to the Reporting Person's continued services through each such date.
Key Figures
Direct common stock holdings: 44,375 shares
Restricted stock units: 34,375 RSUs
Stock options at $1.65: 206,250 underlying shares at $1.65/share
+3 more
6 metrics
Direct common stock holdings
44,375 shares
Total common shares held directly after Form 3
Restricted stock units
34,375 RSUs
Vest in three equal annual installments from Feb 20, 2027
Stock options at $1.65
206,250 underlying shares at $1.65/share
Employee stock option, expiration Mar 25, 2036
Stock options at $1.14
200,000 underlying shares at $1.14/share
Employee stock option, expiration Oct 13, 2034
RSU vesting start
Feb 20, 2027
First of three annual RSU vesting dates
48-month vesting schedule
48 monthly installments
Vesting cadence for one stock option grant from Mar 26, 2026
Key Terms
restricted stock units ("RSUs"), Employee Stock Option (right to buy), vest in 36 equal monthly installments, vest in 48 equal monthly installments
4 terms
restricted stock units ("RSUs") financial
"Includes 34,375 restricted stock units ("RSUs"). The RSUs will vest in three equal annual installments"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Employee Stock Option (right to buy) financial
"security_title": "Employee Stock Option (right to buy)""
vest in 36 equal monthly installments financial
"the remaining shares vested or will vest in 36 equal monthly installments thereafter"
vest in 48 equal monthly installments financial
"The shares subject to the stock option will vest in 48 equal monthly installments"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the OVID Form 3 filing disclose for CFO Charles Ross?
The Form 3 shows CFO Charles Ross’s initial ownership in Ovid Therapeutics. He directly holds 44,375 common shares plus significant stock options and restricted stock units that vest over several years, aligning his compensation with the company’s long-term performance and share value.
What stock options does the OVID CFO hold according to this Form 3?
The CFO holds employee stock options over 206,250 shares at an exercise price of $1.65 and 200,000 shares at $1.14. These options give him the right to buy common stock at those prices before their respective expirations in 2036 and 2034, subject to vesting.
When do Charles Ross’s restricted stock units in Ovid Therapeutics vest?
The 34,375 restricted stock units vest in three equal annual installments starting February 20, 2027. Each installment requires Charles Ross to remain in continuous service with Ovid Therapeutics through the applicable vesting date, reinforcing a long-term service and retention incentive.
What are the vesting terms for the OVID CFO’s $1.14 stock options?
The stock options with a $1.14 exercise price vest over 48 equal monthly installments beginning March 26, 2026. Vesting continues each month as long as Charles Ross remains in service, gradually increasing his right to purchase Ovid Therapeutics common shares at that set price.
Do any of the CFO’s OVID stock options vest before 2026?
Yes. For one option grant, 25% of the shares vested on October 14, 2025. The remaining shares from this grant vest in 36 equal monthly installments afterward, contingent on his continued service, steadily expanding his exercisable position in Ovid Therapeutics common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
